Edgewise Therapeutics (EWTX) to Release Quarterly Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Edgewise Therapeutics to post earnings of ($0.50) per share for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its earnings results on Thursday, February 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, analysts expect Edgewise Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Stock Performance

Shares of Edgewise Therapeutics stock traded down $0.60 during midday trading on Wednesday, reaching $37.41. 676,478 shares of the company’s stock traded hands, compared to its average volume of 1,007,096. The company has a market cap of $4.02 billion, a price-to-earnings ratio of -22.99 and a beta of 0.25. The company’s 50 day simple moving average is $31.28 and its 200 day simple moving average is $26.52. Edgewise Therapeutics has a 52 week low of $12.15 and a 52 week high of $39.96.

Insider Buying and Selling

In related news, CMO Joanne M. Donovan sold 50,000 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the chief marketing officer owned 4,367 shares in the company, valued at approximately $168,435.19. This represents a 91.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 83,892 shares of company stock worth $3,018,216 in the last ninety days. Corporate insiders own 23.20% of the company’s stock.

Institutional Trading of Edgewise Therapeutics

A number of large investors have recently added to or reduced their stakes in EWTX. Canada Pension Plan Investment Board bought a new position in Edgewise Therapeutics during the second quarter worth about $45,000. Jones Financial Companies Lllp bought a new position in Edgewise Therapeutics during the 1st quarter worth approximately $47,000. Steward Partners Investment Advisory LLC raised its holdings in Edgewise Therapeutics by 23.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock worth $71,000 after purchasing an additional 550 shares during the last quarter. Strs Ohio bought a new position in Edgewise Therapeutics during the 1st quarter worth approximately $84,000. Finally, BNP Paribas Financial Markets raised its holdings in Edgewise Therapeutics by 48.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,193 shares of the company’s stock worth $107,000 after purchasing an additional 2,689 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on EWTX shares. JPMorgan Chase & Co. boosted their price target on shares of Edgewise Therapeutics from $34.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, March 17th. Wall Street Zen lowered shares of Edgewise Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Piper Sandler reiterated an “overweight” rating on shares of Edgewise Therapeutics in a research report on Monday, February 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Monday, April 20th. Finally, Stifel Nicolaus set a $25.00 target price on shares of Edgewise Therapeutics in a research report on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.13.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.